CSF and serum total-tau and phospho-tau(181P) in MS patients

• Authors: Jacek Jaworski , Marek Psujek , Halina Bartosik-Psujek
• Languages of publication: EN

Abstracts

EN

In search of biological marker in multiple sclerosis (MS), total-tau and phospho-tau (Thr181) concentrations were established in CSF and serum of 78 patients with MS, using commercially available kits. Serum and CSF concentrations of IgG, IgM, and albumin were assayed simultaneously to calculate quotients and indices of intrathecal synthesis. Serum t-tau detection was strikingly low (23.1%); therefore, this factor was excluded from further analysis. Serum p-tau levels did not correlate with any of indices or quotients. Unexpectedly, CSF t-tau and p-tau showed an inverse relation with MSSS and EDSS, which has not been published elsewhere. Our results do not support utility of serum t-tau and p-tau as surrogate markers for MS.

Keywords

EN

Tau protein; Phospho-tau protein; Multiple sclerosis

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2011
• Volume: 6
• Issue: 2
• Pages: 193-200

Dates

published

1 - 4 - 2011

online

17 - 2 - 2011

Contributors

author

Jacek Jaworski

• Department of Neurology, Medical University of Lublin, 20-954, Lublin, Poland

author

Marek Psujek

• 2nd Department of Anaesthesiology and Intensive Care, Medical University of Lublin, 20-081, Lublin, Poland

author

Halina Bartosik-Psujek

• Department of Neurology, Medical University of Lublin, 20-954, Lublin, Poland

References

• [1] De Stefano N., Matthews P. M., Fu L., Narayanan S., Stanley J., Francis G. S., Antel J. P. et al., Axonal damage correlates with disability in patients with repalsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study, Brain, 1998; 121, 1469–1477 http://dx.doi.org/10.1093/brain/121.8.1469[Crossref]
• [2] Roxburgh R. H., Seaman S. R., Masterman T., Hensiek A. E., Sawcer S. J., Vukusic S. et al., Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity, Neurology, 2005, 64, 1144–1151 [Crossref]
• [3] Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 1983, 33, 1444–1452 [Crossref]
• [4] Pachner A. R., Steiner I., The multiple sclerosis severity score (MSSS) predicts disease severity over time, J. Neurol. Sci., 2009, 278, 66–70 http://dx.doi.org/10.1016/j.jns.2008.11.020[Crossref]
• [5] Weingarten M. D., Lockwood A. H., Hwo S-Y., Kirschner M. W., A protein factor essential for microtubule assembly, Proc. Nat. Acad. Sci. USA, 1975, 72, 1858–1862 http://dx.doi.org/10.1073/pnas.72.5.1858[Crossref]
• [6] Trojanowski J. Q., Schuck T., Schmidt M. L., Lee V. M., Distribution of tau proteins in the normal human central and peripheral nervous system, J. Histochem. Cytochem., 1989, 37, 209–215 [Crossref]
• [7] Avila J., Lucas J. J., Perez M., Hernandez F., Role of tau protein in both physiological and pathological processes. Physiol. Rev., 2004, 84, 361–384 http://dx.doi.org/10.1152/physrev.00024.2003[Crossref]
• [8] Ibach B., Binder H., Dragon M., Poljansky S., Haen E., Schmitz E., et al., Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample, Neurobiol. Aging, 2006, 27, 1202–1211 http://dx.doi.org/10.1016/j.neurobiolaging.2005.06.005[Crossref]
• [9] Skinningsrud A., Stenset V., Gundersen A. S., Fladby T., Cerebrospinal fluid markers in Creutzfeldt-Jakob disease, Cer. Fluid. Res., 2008, 5, 1–8 http://dx.doi.org/10.1186/1743-8454-5-1[Crossref]
• [10] Süssmuth S. D., Reiber H., Tumani H., Tau protein in cerebrospinal fluid (CSF): a blood-CSF related evaluation in patients with various neurological disease, Neurosci. Lett., 2001, 300, 95–98 http://dx.doi.org/10.1016/S0304-3940(01)01556-7[Crossref]
• [11] Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E. et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett., 2001, 297, 187–190 http://dx.doi.org/10.1016/S0304-3940(00)01697-9[Crossref]
• [12] Zelman F. P., Jauch E. C., Mulchahey J. J., Gabbita S. P., Rosenberg W. S., Speciale S. G.et al., C-tau biomarker of neuronal damage is severe brain injured patients: association with elevated intracranial pressure and clinical outocome, Brain Res., 2002, 947, 131–139 http://dx.doi.org/10.1016/S0006-8993(02)02920-7[Crossref]
• [13] Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P. R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 2000, 33, 95–130 http://dx.doi.org/10.1016/S0165-0173(00)00019-9[Crossref]
• [14] Hernández F., Pérez M., de Barreda E. G., Goñi-Oliver P., Avila J., Tau as a molecular marker of development, aging and neurodegenerative disorders, Curr. Aging Sci., 2008, 1: 56–61
• [15] Hein (nee Maier) K., Köhler A., Diem R., Sättler M. B., Demmer I., Lange P. et al., Biological markers for axonal degeneration in CSF and blood of patients with first event indicative for multiple sclerosis, Neurosci. Lett., 2008, 436, 72–76 http://dx.doi.org/10.1016/j.neulet.2008.02.064[Crossref][WoS]
• [16] Reiber H., Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics, Rest. Neurol. Neurosci., 2003, 21: 79–96
• [17] Polman C. H., Reingold S. C., Edan G., Fillipi M., Hartung H. P., Kappos L. et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“, Ann. Neurol., 2005, 58: 840–846 http://dx.doi.org/10.1002/ana.20703[Crossref]
• [18] Reiber H., Peter J. B., Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs, J. Neurol. Sci., 2001, 184: 101–122 http://dx.doi.org/10.1016/S0022-510X(00)00501-3[Crossref]
• [19] Jiménez-Jiménez F. J., Zurdo J. M., Hernanz A., Medina-Acebrón S., de Bustos F., Barcenilla B. et al., Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis, Acta Neurol. Scand., 2002, 106, 351–354 http://dx.doi.org/10.1034/j.1600-0404.2002.01370.x[Crossref]
• [20] Guimarães J., Cardoso M. J., Sá M. J., Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis, Mult. Scler., 2006; 12, 354–356 http://dx.doi.org/10.1191/1352458506ms1288sr[Crossref]
• [21] Valis M., Talab R., Stourac P., Andrys C., Masopust J., Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients, Neuro. Endocrinol. Lett., 2008, 29, 971–976
• [22] Kapaki E., Paraskevas G. P., Michalopoulou M., Kilidireas K., Increased cerebrispinal fluid tau protein in multiple sclerosis, Eur. Neurol., 2000, 43, 228–232 http://dx.doi.org/10.1159/000008181[Crossref]
• [23] Terzi M., Birinci A., Çetinkaya E., Onar M. K., Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis, Acta Neurol. Scand., 2007, 115, 325–330 http://dx.doi.org/10.1111/j.1600-0404.2007.00782.x[Crossref]
• [24] Brettschneider J., Maier M., Arda S., Claus A., Süssmuth S. D., Kassubek J. et al., Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis, Mult. Scler., 2005, 11, 261–265 http://dx.doi.org/10.1191/1352458505ms1159oa[Crossref]
• [25] Rostazy K., Withhut E., Pohl D., Lange P., Cisielcyk B., Diem R. et al., Tau, phospho-tau and S-100B in cerebrospinal fluid of children with multiple sclerosis, J. Child. Neurol., 2005, 20, 822–825 http://dx.doi.org/10.1177/08830738050200100801
• [26] Teunissen C. E., Dijkstra C., Polman C., Biological markers in CSF and blood for axonal degeneration in multiple sclerosis, Lancet Neurol., 2005, 4, 32–41 http://dx.doi.org/10.1016/S1474-4422(04)00964-0[Crossref]
• [27] Anderson J. M., Patani R., Reynolds R., Nicholas R., Compston A., Spillantini M. G. et al., Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis, Acta Neuropathol., 2009, 117, 583–589 http://dx.doi.org/10.1007/s00401-009-0515-2[Crossref][WoS]
• [28] Anderson J. M., Hampton D. W., Patani R., Pryce G., Crowther R. A., Reynolds R. et al., Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis, Brain, 2008, 131, 1736–48 http://dx.doi.org/10.1093/brain/awn119[WoS][Crossref]
• [29] Andersson M., Alvarez-Cermeño J., Bernardi G., Cogato I., Fredman P., Frederiksen J, Fredrikson S. et al., Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report, J. Neurol. Neurosurg. Psychiatry, 1994, 57, 897–902 http://dx.doi.org/10.1136/jnnp.57.8.897[Crossref]
• [30] Zemlan F. P., Rosenberg W. S., Luebbe P. A., Campbell T. A., Dean G. E., Weiner N. E. et al., Quantification od axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins, J. Neurochem., 1999, 72, 741–750 http://dx.doi.org/10.1046/j.1471-4159.1999.0720741.x[Crossref]
• [31] Ingelson M., Blomberg M., Benedikz E., Wahlund L-O., Karlsson E., Vanmechelen E. et al., Tau immunoreactivity detected in human plasma, but no obvious increase in dementia, Dement Geriatr Cogn Disord, 1999, 10, 442–445 http://dx.doi.org/10.1159/000017187[Crossref]
• [32] Bakshi R., Dandamudi Venkata S. R., Neema M., De C., Bermel R. A., Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis, J Neuroimaging, 2005, 15, 30S–45S http://dx.doi.org/10.1177/1051228405283901[Crossref]
• [33] Jasperse B., Jakobs C., Eikelenboom M. J., Dijkstra C. D., Uitdehaag B. M. J., Barkhoff F. et al., N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gaschromatography-mass spectrometry, J Neurol, 2007, 254, 631–637 http://dx.doi.org/10.1007/s00415-006-0415-5[WoS][Crossref]
• [34] Tenissen C. E., Iacobaeus E., Khademi M., Brundin L., Norgren N., Koel-Simmelink M. J. A. et al., Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis, Neurology, 2009, 72, 1322–1329 http://dx.doi.org/10.1212/WNL.0b013e3181a0fe3f[WoS][Crossref]
• [35] Compston A., Lassmann H., Smith K., Differences between acute, relapsing and progressive multiple sclerosis, In: Compston A., Confavreux C., Lassmann H., McDonald I., Miller D., Noseworthy J. et al., McAlpine’s Multiple Sclerosis, 4th Ed., Churchill Livingstone Elsevier, Oxford, UK, 2005, 594–596
• [36] Ott B. R., Cohen R. A., Gongvatana A., Okonkwo O. C., Johanson C. E., Stopa E. G. et al., Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer’s disease, J Alzheimer Dis, 2010, 20, 647–657
• [37] Fagan A. M., Head D., Shah A. R., Marcus D., Mintun M., Morris J. C. et al., Decreased CSF Aβ42 correlates with brain atrophy in cognitively normal elderly, Ann Neurol, 2009, 65, 176–183 http://dx.doi.org/10.1002/ana.21559[WoS][Crossref]
• [38] Tosun D., Schuff N., Truran-Sacrey D., Shaw L. M., Trojanowski J. Q., Aisen P. et al, Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal study, Neurobiol Aging, 2010, 31, 1340–1354 http://dx.doi.org/10.1016/j.neurobiolaging.2010.04.030[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-011-0003-7